Zim Laboratories Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹614 Cr
The company expects a 25%-30% CAGR growth over the next few years, driven mainly by fast-growing NIP (Novel Innovative Products) and OTF (Orally Thin Film) products. ZIM expects a growth rate of 25% to 30% CAGR in revenues over the next few years, driven largely by NIP and OTF products expanding to 30%-40% of total turnover by FY26-FY27.
From Zim Laboratories Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹125
Market Cap
₹614 Cr
P/E Ratio
141.2
How does Zim Laboratories Ltd rank in Pharmaceuticals & Biotechnology?
Compare Zim Laboratories Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Zim Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹105 Cr, net profit ₹4 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company expects a 25%-30% CAGR growth over the next few years, driven mainly by fast-growing NIP (Novel Innovative Products) and OTF (Orally Thin Film) products.
- →NIP and OTF currently contribute about 16%-19% of sales, projected to increase to 30%-40% in the coming years, potentially reaching 50% over time.
- →Growth will come from regulated markets (Europe, Australia, UK) as well as emerging and RoW (Rest of World) markets.
- →Base/legacy business is expected to stabilize with nominal growth, recovering to past levels after recent challenges.
- →Revenue increase also depends on successful regulatory approvals, especially in Europe.
- →Overall top-line growth and EBITDA margin improvement to upper teens are anticipated with better product mix and operational efficiencies.
📈 Profitability & Margins
- →ZIM expects a growth rate of 25% to 30% CAGR in revenues over the next few years, driven largely by NIP and OTF products expanding to 30%-40% of total turnover by FY26-FY27.
- →EBITDA margins are projected to improve to the upper teens (around 15%-17%) as higher-margin NIP/OTF products scale up and operating costs remain rationalized.
- →FY26 and FY27 are anticipated as inflection points for margin improvement and revenue growth, contingent on regulatory approvals and market launches by end of Q3/Q4 FY26.
- →Significant CapEx has already been completed; future CapEx will focus only on technology upgrades.
- →Legacy business stabilizing with nominal growth expected, complementing the high-growth new product lines.
- →Earnings and margins gains are realistic given rationalized operating expenses, increasing contribution of patented products, and a broader regulated and emerging markets footprint.
🏗️ Capital Expenditure Plans
- →Major CapEx has already been completed, focusing on upgradation and technology improvement going forward (Page 21, 24).
- →No further major CapEx or new big projects planned; future CapEx limited to facility upgrades (Page 21, 24).
- →Capacity utilization currently low; newly built capacity will be better utilized once marketing authorizations (MAs) are received (Page 20, 24).
- →Strategic focus on expanding geographical footprint and entering regulated markets with NIP and OTF products; investments aligned accordingly (Page 23, 18).
- →Marketing and sales expansion ongoing, including hiring marketing teams and appointing domestic out-licensing executives (Page 16, 24).
- →No current plans for deleveraging; financing so far through internal accruals and borrowings with CapEx closed (Page 20, 24).
💰 Fundraising & Capital Structure
- →No plans for deleveraging or increasing borrowings as of now.
- →CapEx has been largely completed, and future CapEx will be limited to upgrades and technology improvements only.
- →All major CapEx financed through a mix of internal accruals and borrowings already secured.
- →No further major projects or large fundraising through debt or equity planned at this moment.
📋 Order Book & Pipeline
- →There was a significant order from the Government of Maharashtra worth around INR 20 crores that got deferred due to the election year in FY25.
- →This order did not get deferred to the next year, impacting the domestic revenue temporarily.
- →The legacy business faced some delays related to currency issues with a large client, which have now been resolved.
- →The company expects the legacy business orders to come back to previous levels with nominal growth.
- →Production schedules for new products depend largely on marketing partners' readiness, with manufacturing expected to start once orders are received.
- →Regulatory approvals (Marketing Authorizations) are still pending for some markets, especially in Europe, which could affect timelines.
- →Overall, the company is optimistic about new order inflows starting Q3 FY26 with multiple partners on a nonexclusive basis to mitigate risks.
Key Metrics
Frequently Asked Questions
What were Zim Laboratories Ltd Q4 FY25 results?
The company expects a 25%-30% CAGR growth over the next few years, driven mainly by fast-growing NIP (Novel Innovative Products) and OTF (Orally Thin Film) products. ZIM expects a growth rate of 25% to 30% CAGR in revenues over the next few years, driven largely by NIP and OTF products expanding to 30%-40% of total turnover by FY26-FY27.
What is Zim Laboratories Ltd share price analysis?
Zim Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 141.2 with a market cap of ₹614 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zim Laboratories Ltd planning capital expenditure?
Major CapEx has already been completed, focusing on upgradation and technology improvement going forward (Page 21, 24).
Keep Zim Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.